Cargando…

Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial

BACKGROUND: Currently, there are no specific effective treatments for SARS-CoV-2 infection; however, various COVID-19 treatment options are under investigation. It is vital to continue investigating the landscape of SARS-CoV-2–induced pneumonia and therapeutic interventions. OBJECTIVE: This paper pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terada-Hirashima, Junko, Suzuki, Manabu, Uemura, Yukari, Hojo, Masayuki, Mikami, Ayako, Sugiura, Wataru, Ohmagari, Norio, Sugiyama, Haruhito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JMIR Publications 2020
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781585/ https://www.ncbi.nlm.nih.gov/pubmed/33206053 http://dx.doi.org/10.2196/23830

Ejemplares similares

Efficacy and Safety of Direct Hemoperfusion Using Polymyxin B-Immobilized Polystyrene Column for Patients With COVID-19: Protocol for an Exploratory Study
por: Terada-Hirashima, Junko, et al.
Publicado: (2022)

A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT)
por: Tomita, Noriko, et al.
Publicado: (2022)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA)
por: Terayama, Yuriko, et al.
Publicado: (2022)

Efficacy and Safety of the Smallpox Vaccine for Postexposure Prophylaxis in Monkeypox: Protocol for an Open-Labeled, Single-Armed Study
por: Yano, Rina, et al.
Publicado: (2023)

An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox
por: Tomita, Noriko, et al.
Publicado: (2023)

A randomized clinical trial on inhaled ciclesonide for managing acute asthma in the emergency room
por: Martins, Demétrius Tierno, et al.
Publicado: (2022)

Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan
por: Matsunaga, Nobuaki, et al.
Publicado: (2020)

Evaluating the Immunogenicity and Safety of a Smallpox Vaccine to Monkeypox in Healthy Japanese Adults: A Single-Arm Study
por: Tomita, Noriko, et al.
Publicado: (2023)

Is there a role for inhaled ciclesonide in the treatment of COVID-19?
por: Salvi, Sundeep Santosh
Publicado: (2021)

From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled corticosteroids
por: Nave, Ruediger, et al.
Publicado: (2013)

Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma
por: Schaffner, Timothy J, et al.
Publicado: (2009)

Inhaled ciclesonide for outpatients with COVID-19: A meta-analysis
por: Hsu, Chi-Kuei, et al.
Publicado: (2022)

Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial
por: Ezer, Nicole, et al.
Publicado: (2021)

Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial
por: Song, Joon-Young, et al.
Publicado: (2021)

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review
por: Dyer, Matthew J, et al.
Publicado: (2006)

The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide?
por: van der Molen, Thys, et al.
Publicado: (2014)

Inhaled ciclesonide is efficacious and well tolerated in the treatment of severe equine asthma in a large prospective European clinical trial
por: Pirie, Robert Scott, et al.
Publicado: (2021)

Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)
por: Duvignaud, Alexandre, et al.
Publicado: (2022)

Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19)
por: Brodin, Daniel, et al.
Publicado: (2023)

Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases
por: Iwabuchi, Keisuke, et al.
Publicado: (2020)

Clinical experience with high-flow nasal cannulas for coronavirus disease 2019 patients in Japan
por: Katsuno, Takashi, et al.
Publicado: (2021)

Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan
por: Tanaka, Akihito, et al.
Publicado: (2021)

Ciclesonide for the treatment of asthma
por: Dahl, Ronald
Publicado: (2006)

Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids
por: Postma, Dirkje S., et al.
Publicado: (2017)

Similar Results in Children with Asthma for Steady State Pharmacokinetic Parameters of Ciclesonide Inhaled with or without Spacer
por: Boss, H., et al.
Publicado: (2010)

Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study
por: Kuo, Kuan-Chih, et al.
Publicado: (2022)

Intranasal ciclesonide for allergic rhinitis
por: Williams, Ben, et al.
Publicado: (2008)

The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells
por: Matsuyama, Shutoku, et al.
Publicado: (2020)

Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa
por: Sato, Hideyuki, et al.
Publicado: (2007)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)

Molecular pharmacology of ciclesonide against SARS-CoV-2
por: Kimura, Hirokazu, et al.
Publicado: (2020)

Unexpected Bronchial Foreign Body Aspiration
por: Suzuki, Manabu, et al.
Publicado: (2020)

Profile of ciclesonide for the maintenance treatment of asthma
por: Singas, Effie, et al.
Publicado: (2011)

Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study
por: Yamamoto, Shohei, et al.
Publicado: (2021)

Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial
por: Saito, Sho, et al.
Publicado: (2023)

Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Efficacy of ciclesonide in the treatment of patients with asthma exacerbation
por: Zietkowski, Ziemowit, et al.
Publicado: (2019)

Successful Recovery from COVID-19-associated Acute Respiratory Failure with Polymyxin B-immobilized Fiber Column-direct Hemoperfusion
por: Kusaba, Yusaku, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dmpl11pdf6joksh638qbe9eove